Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers ...

Shares of GSK PLC GSK inched up 0.59% to £13.64 Thursday, on what proved to be an all-around positive trading session for the ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

GSK PLC GSK shares shed 2.82% to £12.94 Tuesday, on what proved to be an all-around rough trading session for the stock ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...